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Abstract
Introduction: Immune checkpoint inhibitors including nivolumab, an antibody against programmed death-1, have been
increasingly introduced in various cancer treatment regimens, and are reported to be associated with immune-related adverse
events. Nivolumab-induced renal injury is generally caused by acute interstitial nephritis and is managed by drug discontinuation and
steroid therapy. Although this agent can infrequently induce glomerulonephritis, the pathogenesis and therapeutic strategy remain
undetermined.
Patient concerns: A 78-year-old man was diagnosed with advanced gastric cancer with portal thrombosis. First- and second-
line chemotherapies were ineffective; thus, nivolumab monotherapy was initiated. Although it effectively prevented tumor growth,
proteinuria and microhematuria appeared 2 months later. Despite drug discontinuation, serum creatinine progressively increased
from 0.72 to 1.45mg/dL. Renal biopsy revealed mesangial IgA and C3 deposition in immunofluorescence analysis and mesangial
proliferation with crescent formation in light microscopy.
Diagnosis: The patient was diagnosed with IgA nephropathy. Based on the temporal relationship between the nivolumab therapy
and abnormal urinalysis, IgA nephropathy was considered to have been induced by nivolumab.
Interventions: A moderate dose (0.6mg/kg/day) of prednisolone was orally administrated, with tapering biweekly.
Outcomes:Steroid therapy stabilized his serum creatinine levels andmarkedly reduced proteinuria. However, bacterial pneumonia
substantially impaired his performance status; thus, nivolumab could not be restarted despite tumor regrowth.
Lessons: IgA nephropathy should be recognized as an uncommon renal adverse event during nivolumab therapy. After drug
discontinuation, nivolumab-induced IgA nephropathy is likely to respond to moderate doses of steroid therapy with early tapering.
However, more evidence is needed to determine whether nivolumab can be safely restarted during or after steroid therapy.
Abbreviations: ANCA = anti-neutrophil cytoplasmic antigen, ATN = acute tubular necrosis, CTLA-4 = cytotoxic T-lymphocyte-
associated protein-4, IgG4 = immunoglobulin G4, irAEs = immune-related adverse events, PD-1 = programmed death-1.
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1. Introduction
Traditional chemotherapy using cytotoxic agents, such as
cisplatin, has been associated with renal injury.[1] In most cases,
renal histology is consistent with acute tubular necrosis (ATN).
As drug discontinuation is the only therapeutic approach to
chemotherapy-associated ATN, renal injury greatly limits cancer
treatment.[2] In the past decade, a variety of molecular targeting
drugs were introduced into clinical practice. Some of these drugs,
such as vascular endothelial growth factor receptor or epidermal
growth factor receptor blocking agents, can induce glomerular
injury rather than ATN.[3] Histological evaluation is increasingly
important to clarify the pathogenesis of chemotherapy-associated
renal injury.
Nivolumab is a fully human immunoglobulin G4 (IgG4)
antibody directed against programmed death -1 (PD-1). PD-1 is a
negative regulatory receptor expressed on the surface of activated
T cells and B cells; thus it acts as an immune checkpoint.[4]
Inhibitory effects of nivolumab on immune checkpoints enhance
the antineoplastic immune response.[5] Cytotoxic T-lymphocyte-
associated protein-4 (CTLA-4) is another immune checkpoint;
additionally, human anti-CTLA-4 IgG1 antibody, ipilimumab,
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has antineoplastic activity.[5] These immune checkpoint inhibitors
have been incorporated into many cancer treatment regimens.
However, owing to their ability to enhance immune responses,
anticancer therapies with immune checkpoint inhibitors are
sometimes associated with various immune-related adverse events
(irAEs), including thyroid disorders, type 1 diabetes mellitus,
colitis, encephalitis, and interstitial pneumonitis.[6]
Although the kidney is infrequently involved in immune
checkpoint inhibitor-induced irAEs, nivolumab can cause acute
kidney injury due to acute interstitial nephritis in most cases with
renal events.[7] Such acute kidney injury events can be managed
by drug discontinuation and/or steroid therapy. However,
according to some recent case reports, nivolumab may be
associated with glomerular disorders, including nephrotic
syndrome and glomerulonephritis.[8] Unfortunately, nivolu-
mab-induced glomerular disorders and their therapeutic strate-
gies have not been well characterized, compared to acute
interstitial nephritis, due to insufficient data. In this case report,
we present a patient who was diagnosed with IgA nephropathy
after nivolumab therapy against advanced gastric cancer and
discuss the pathogenesis and potential therapeutic strategy.
Written informed consent was provided by the patient for
publication of this case report.
2. Case presentation
A 78-year-old Japanese man with type 2 diabetes mellitus was
diagnosed with advanced gastric cancer and portal vein tumor
thrombus (T3, N3, M1; stage IV) in August 2017. His
hemoglobin A1c level was well controlled in the range of
5.7% to 6.0% by the administration of 5mg/day of linagliptin.
First-line (S-1 + oxaliplatin) and second-line (ramucirumab +
paclitaxel) chemotherapies were discontinued owing to disease
progression, and nivolumab monotherapy (240mg, biweekly)
was started as third-line therapy in September 2018. Until then,
urinalysis revealed only trace proteinuria and his serum
creatinine concentration was between 0.64 and 0.72mg/dL.
Nivolumab therapy effectively prevented the growth of the
primary gastric tumor and normalized the elevated tumor
marker; the serum level of carcinoembryonic antigen decreased
from 41.8ng/mL to 4.9ng/mL. However, 2 months later, urinary
protein 2+ and occult blood 2+ were noted in dipstick tests.
Nivolumab administration was discontinued owing to the
development of bacterial pneumonia in February 2019; the drug
was decided to be withheld until his performance status
improved. Nevertheless, the patient presented with massive
proteinuria (3+ on dipstick; urinary protein to creatinine ratio,
3.59g/g of creatinine) and hematuria (>100/high power field)
and showed an increased serum creatinine concentration up to
1.45mg/dL in May 2019 (Fig. 1).
At the time of nephrology consultation, his blood pressure was
132/70 mmHg and heart rate was 88beats/min; he had mild
pitting edema and no purpura in the lower limbs. In addition to
renal dysfunction and proteinuria, as mentioned above, anemia
associated with gastric cancer was observed; moreover, the liver
function test and electrolyte panel were within the normal range.
In the immunological evaluation, serum IgA was increased to
538.8mg/dL, complement levels were normal (IgA/C3 ratio was
6.24), and cryoglobulin, anti-nuclear antibody, and both
myeloperoxidase- and proteinase 3-anti-neutrophil cytoplasmic
antigen (ANCA) were negative. Renal morphology on abdominal
computed tomography was normal. Renal biopsy was performed
for histological evaluation. Immunofluorescence revealed IgA
and C3 depositions in the mesangial area (Fig. 2A and B,
respectively). Light microscopy revealed moderate tubular
atrophy and focal interstitial inflammatory infiltration on
Masson trichrome staining (Fig. 2C) and mesangial proliferation
with fibro-cellular crescent formation on Periodic-Schiff staining
(Fig. 2D). Electron microscopy revealed dense deposits in the
paramesangial area (Fig. 2E; indicated by arrows). Based on these
Figure 1. Clinical course and treatments of the patient. U-Pro=urinary protein, U-OB=urinary occult blood.
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histological findings, the patient was diagnosed with IgA
nephropathy (MSET-C score; M1, S0, E0, T1, C1). Based on
the temporal relationship between the nivolumab therapy and
abnormal urinalysis, IgA nephropathy was considered to have
been induced by nivolumab.
During the discontinuation of nivolumab, tumor regrowth was
observed. However, retreatment with nivolumab was limited by
the progressive renal injury. To prevent the deterioration of renal
function, a moderate dose of prednisolone (0.6mg/kg of body
weight/day) was orally administered from June 2019. Steroid
therapy with tapering biweekly stabilized his serum creatinine
concentration between 1.2 and 1.4mg/dL and markedly
decreased his proteinuria to 0.18g/g of creatinine (Fig. 1). The
initial increase in blood glucose needed temporary insulin
therapy, but hyperglycemia was promptly improved with steroid
tapering and could be managed using original diabetic medica-
tion. Although nivolumab re-administration was considered to
prevent tumor regrowth, bacterial pneumonia recurrence
substantially impaired his performance status; thus, it was
difficult to reinitiate nivolumab therapy despite the stabilization
of his renal function.
3. Discussion
Immune checkpoint inhibitors, including nivolumab, have been
increasingly associated with various irAEs in cancer patients,
Figure 2. (A, B) Immunofluorescence image for IgA and C3 deposition, respectively (original magnification 400). (C) Masson-trichrome staining showing tubular
atrophy and focal inflammatory infiltration (original magnification100). (D) Periodic acid-Schiff staining of glomerulus with mesangial proliferation and fibro-cellular
crescent (original magnification 400). (E) Electron microscopic image showing paramesangial electron dense deposits (arrows, original magnification 8000).
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with the expansion of their indications. Notably, some clinical
studies have shown that the development of irAEs is associated
with better prognosis,[9,10] suggesting the importance of irAE
management during immune checkpoint inhibitor therapy. The
incidence of renal involvement related to nivolumab mono-
therapy was estimated to be approximately 2%.[11] However, a
recent report suggests that low-grade renal involvements may be
underestimated in nivolumab therapy.[7] In contrast to other
irAEs such as thyroid disorder and diabetes mellitus, there has
been no evidence that nivolumab-induced renal adverse events
can be associated with better patient survival. Nevertheless, it is
critical, for the continuation of cancer chemotherapy, that the
progression of renal injury is effectively managed.
The most commonly reported renal involvements in nivolumab
therapy is acute interstitial nephritis.[7] In this process, nivolumab
is postulated to induce direct lymphocyte infiltration into the renal
interstitium or enhance the potential interstitial nephritis due to
other medications.[12,13] Recent case reports and case series have
suggested that nivolumab may be associated with glomerulone-
phritis. According to a recent literature review,[8] nivolumab
monotherapy or combined therapywith other immune checkpoint
inhibitors can induce ANCA-positive or ANCA-negative necro-
tizing glomerulonephritis. Furthermore, 2 cases of biopsy-proven
IgA nephropathy associated with nivolumab therapy as mono-
therapy[14] or in combination with ipilimumab[8] have been
reported.Basedonmanybasic studies, primary IgAnephropathy is
considered to be caused by the production of underglycosylated
IgA1 and autoantibodies directed against such abnormal IgA1
molecules and subsequent immune complex formation and
mesangial deposition, leading to glomerular inflammation.[15]
Therefore, immune disturbance should play a pivotal role in the
pathogenesis of primary IgA nephropathy. Although mechanisms
underlying nivolumab-induced renal injury remain undetermined,
given its higher prevalence in the Asian population,[16] nivolumab
therapy may unmask subclinical IgA nephropathy by enhancing
immune responses.
Therapeutic strategies against nivolumab-induced acute inter-
stitial nephritis have been established and depend on its severity.
Moderate renal injury defined as increased serum creatinine to
two- to three-fold above baseline can be managed by moderate
doses of prednisone (0.5–1mg/kg/day) and withholding nivolu-
mab therapy, whereas severe renal injury with a greater increase
in serum creatinine level should be initially treated with higher
doses of prednisone or methylprednisolone (1–2mg/kg/day) and
withdrawal of nivolumab.[17] The most appropriate strategy by
which nivolumab-induced glomerulonephritis can be managed
remains unclear as there is not much data available in this regard.
Some cases of nivolumab-induced glomerulonephritis were
treated with drug discontinuation and high doses of prednisone
alone or in combination with other immunosuppressants, leading
to complete or partial renal recovery.[8] Although there is still
controversy on whether moderate to high doses of steroids can
promote tumor growth and poor outcomes in patients treated
with nivolumab, obvious deleterious effects of steroid therapy on
the clinical effectiveness of nivolumab in cancer patients have not
been confirmed to date.[18] In the previous two reports on
nivolumab-induced IgA nephropathy mentioned above, the first
case with nivolumab monotherapy was followed by only drug
discontinuation.[14] The patient’s proteinuria was markedly
improved and the increased serum creatinine was stabilized;
this clinical course appears to be opposed to that of the present
case. In the second case of nivolumab therapy combined with
ipilimumab, 0.5mg/kg of body weight/day of prednisone was
administrated in addition to drug discontinuation.[8] Such
treatment was, at least transiently, effective in achieving
remission of glomerulonephritis. Notably, tumor growth during
follow-up after discontinuation of nivolumab was not observed
in either case.[8,14] In contrast, the present case showed both
progressive renal injury and gastric tumor growth during
nivolumab withdrawal. Despite improvement of glomerulone-
phritis by steroid therapy, nivolumab re-administration was
withheld due to impaired performance status. As most cases of
nivolumab-induced glomerulonephritis to date required drug
discontinuation regardless of prednisone treatment,[8] whether
nivolumab can be safely re-administrated after or during steroid
therapy without relapse of glomerulonephritis remains unclear.
4. Conclusion
In conclusion, it should be recognized that IgA nephropathy may
be an uncommon irAE associated with nivolumab therapy and
progressive glomerular injury limits the continuation of cancer
treatment. This irAE can be controlled by nivolumab discontin-
uation and moderate doses of steroid therapy with early tapering.
However, whether nivolumab therapy can be safely restarted
remains unclear. Case reports of nivolumab-induced glomerulo-
nephritis, including IgA nephropathy, must be accumulated to
determine the appropriate therapeutic strategies.
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